4.3 Article

Mitochondrial Dysfunction, Insulin Resistance, and Type 2 Diabetes Mellitus

期刊

CURRENT DIABETES REPORTS
卷 8, 期 3, 页码 173-178

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-008-0030-1

关键词

-

资金

  1. Bristol-Myers Squibb
  2. Amylin
  3. Eli Lilly Co.
  4. Novartis
  5. Pfizer
  6. Takeda

向作者/读者索取更多资源

Insulin resistance is a characteristic feature of type 2 diabetes mellitus, obesity, and the metabolic syndrome. Increased intracellular fat content in skeletal muscle and liver associated with insulin resistance has led to the hypothesis that a mitochondrial defect in substrate oxidation exists in disorders of insulin resistance. In vivo measurements of metabolic fluxes through the tricarboxylic acid and oxidative phosphorylation with magnetic resonance spectroscopy have demonstrated multiple defects in mitochondrial function in skeletal muscle. A decrease in mitochondrial density and mitochondrial copy number has been reported in have not been a consistent observation in all studies. Similarly, an intrinsic functional defect in mitochondrial adenosine triphosphate production synthesis has been reported in some but not all studies. This review summarizes evidence that implicates a defect in mitochondrial oxidative phosphorylation and its relationship to insulin resistance in common metabolic diseases characterized by impaired insulin action.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据